Health and Healthcare

Major Biotechs See Rising Tide in Short Interest

nevodka / iStock

The short interest data are out for the most recent settlement date, October 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.

Amgen Inc. (NASDAQ: AMGN) saw its short interest increase to 9.18 million shares from the previous level of 8.57 million. Shares were last seen trading at $201.70, in a 52-week range of $166.30 to $211.90.

Short interest in Biogen Inc. (NASDAQ: BIIB) dropped to 3.30 million shares from the previous 3.56 million. The stock recently traded at $287.35, within a 52-week range of $215.78 to $344.00.

Celgene Corp.’s (NASDAQ: CELG) short interest for this settlement date increased slightly to 11.82 million shares from the previous level of 11.76 million. Shares were changing hands at $105.02, in a 52-week range of $58.59 to $107.41.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest rise a bit to 13.92 million shares from 13.91 million in the previous period. Shares were trading at $63.08, in a 52-week range of $60.32 to $72.90.

The number of MannKind Corp. (NASDAQ: MNKD) shares short rose to 39.55 million. The previous reading was 39.09 million. The stock traded at $1.27 a share, in a 52-week range of $0.94 to $2.34.

Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest decreased to 2.97 million shares from the previous 3.15 million. Shares were trading at $104.19, in a 52-week range of $92.56 to $141.86.


It’s Your Money, Your Future—Own It (sponsor)

Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.